Oppenheimer Initiates Coverage on OSI Pharmaceuticals (OSIP)
More News related to OSIP
- OSI Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009
- OSI Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference on Tuesday, November 3, 2009
- OSI Pharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
- Galleon Shuttered On Insider Trading Charges
- Trading Radar for 10/21: Boeing (BA), eBay (EBAY), Wells Fargo (WFC), US Bancorp (USB), Eli Lilly (ELY), St. Jude Medical (STJ) Report
More News related to New Coverage
- Enterprise Tech Rebound Is Real - Analyst (HPQ, NTAP, STX, ARW)
- Credit Suisse Boosts Price Target on HP (HPQ) to $60
- Consensus Forms That Despite Tremendous YTD Move, Ford (F) Is Still Undervalued
- Goldman Sachs Adds Smith & Nephew (SNN) To Their Conviction Buy List
- Capital One Southcoast Maintains an 'Add' Rating on Concho Resources (CXO); Raises PT
Oppenheimer initiates coverage on OSI Pharmaceuticals (Nasdaq: OSIP) with a Perform rating.
To see more analyst ratings on OSIP Click Here.
OSI Pharmaceuticals, Inc. (OSI) is a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing unmet medical needs in oncology, diabetes and obesity.
Related Categories
New CoverageStocks Mentioned
-0.41Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
